PHARMAXIS PLANS TRIAL OF CF DRUG

Pharmaxis will initiate two Phase III trials of its potential cystic fibrosis (CF) treatment Bronchitol.

The announcement comes after the firm met with the Food and Drug Administration and the European Medicines Agency about the drug candidate.

Phase II results indicated that Bronchitol, an inhalable dry powder administered by a handheld device, improved lung function in cystic-fibrosis patients. The endpoint of the Phase III trials will be lung function, but the complete protocols are still being finalized.